The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Mecklenburg-Vorpommern; Mecklenburg-Vorpommern; Rostock, Kreisfreie Stadt
Location of affected unit(s)
Rostock
Sector
Manufacturing (20 - 21) Manufacture of chemicals and pharmaceuticals 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
80 jobs Number of planned job losses
Announcement Date
24 November 2021
Employment effect (start)
1 January 2022
Foreseen end date
31 March 2022
Description
Centogene, a German company specialised in diagnostics and research of rare diseases, will be cutting approximately 80 jobs at its site in Rostock. According to the company’s third quarter report, Centogene will phase out its non-core COVID-19 testing services by early 2022 (no exact date available) which will result in the loss of 80 employees out of the 530 people currently employed at the Rostock site.
As of now, there is no information on a social plan available.
Centogene is a global biotechnology company founded in Rostock, Germany with further offices in Germany as well as in US.
Eurofound (2021), Centogene, Internal restructuring in Germany, factsheet number 105864, European Restructuring Monitor. Dublin, https://apps.eurofound.europa.eu/restructuring-events/detail/105864.